Literature DB >> 1675143

Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT1A or 5-HT1D subtype.

M J Perren1, W Feniuk, P P Humphrey.   

Abstract

1. There is controversy about whether 5-HT1A receptors mediate contraction of isolated cerebral blood vessels. We have therefore compared the vascular actions of the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propyl-amino)-tetralin (8-OH-DPAT) with those of the 5-HT1-like receptor agonist, sumatriptan, on the dog isolated saphenous vein, which contains a 5-HT1-like receptor similar to those on cerebral blood vessels, and in the carotid circulation of the anaesthetized dog. 2. 5-Hydroxytryptamine (5-HT), sumatriptan and 8-OH-DPAT each caused contraction of dog isolated saphenous vein with a rank order of agonist potency of 5-HT greater than sumatriptan greater than 8-OH-DPAT and EC50 values (95% confidence limits) of 0.06 (0.04-0.08), 0.3 (0.1-0.8) and 3.9 (2.0-7.5) microM respectively. The maximum contractile effect produced by each agonist was similar. 3. The contractile effects of 5-HT, sumatriptan and 8-OH-DPAT in the dog isolated saphenous vein were resistant to antagonism by the 5-HT1A receptor antagonists spiperone, spiroxatrine and pindolol (all 1 microM). The 5-HT1D receptor ligands, metergoline (0.1 microM) rauwolscine (1 microM) and yohimbine (1 microM) had little or no antagonist activity. In contrast, the non-selective 5-HT1-like receptor blocking drug, methiothepin (0.03-0.3 microM) potently antagonized the contractile effects of 5-HT, sumatriptan and 8-OH-DPAT to a similar degree, suggesting that all three agonists act at the same receptor. 4. In ganglion-blocked, anaesthetized dogs, intra-carotid administration of 8-OH-DPAT (0.3-3 pggkg-1) and sumatriptan (0.1l-1 pgkg -), caused dose-dependent carotid arterial vasoconstriction. The two agonists were approximately equipotent in this respect. 5. The carotid arterial vasoconstrictor actions of 8-OH-DPAT and sumatriptan were not modified by spiperone (1 mgkg- , i.v.) but were antagonized to a similar extent by the subsequent administration of methiothepin (1 mgkg- 1, i.v.). 6. These results suggest that 8-OH-DPAT contracts the dog isolated saphenous vein and constricts the carotid arterial circulation of anaesthetized dogs by activation of 5-HT1-like receptors which are not of the 5-HTlA subtype, nor, on the basis of data with metergoline in the dog isolated saphenous vein, of the 5-HTID subtype. The receptor involved in these actions appears to be the same as that mediating the vasoconstrictor effects of sumatriptan. This receptor does not appear to be like any known 5-HT1 ligand binding site; hence the current description, 5-HT1-like, remains the most appropriate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675143      PMCID: PMC1917870          DOI: 10.1111/j.1476-5381.1991.tb12152.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Evidence that the putative 5-HT1A receptor agonists, 8-OH-DPAT and ipsapirone, have a central hypotensive action that differs from that of clonidine in anaesthetised cats.

Authors:  A G Ramage; J R Fozard
Journal:  Eur J Pharmacol       Date:  1987-06-19       Impact factor: 4.432

2.  Characterization of the 5-hydroxytryptamine1a receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes.

Authors:  M De Vivo; S Maayani
Journal:  J Pharmacol Exp Ther       Date:  1986-07       Impact factor: 4.030

3.  Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.

Authors:  P B Bradley; G Engel; W Feniuk; J R Fozard; P P Humphrey; D N Middlemiss; E J Mylecharane; B P Richardson; P R Saxena
Journal:  Neuropharmacology       Date:  1986-06       Impact factor: 5.250

4.  Pharmacological analysis of muscarinic receptors coupled to oxyntic cell secretion in the mouse stomach.

Authors:  J W Black; N P Shankley
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

5.  Dissociation constants of serotonin agonists in the canine basilar artery correlate to Ki values at the 5-HT1A binding site.

Authors:  E W Taylor; S P Duckles; D L Nelson
Journal:  J Pharmacol Exp Ther       Date:  1986-01       Impact factor: 4.030

6.  Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin.

Authors:  D Hoyer; G Engel; H O Kalkman
Journal:  Eur J Pharmacol       Date:  1985-11-26       Impact factor: 4.432

7.  Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes.

Authors:  R E Heuring; S J Peroutka
Journal:  J Neurosci       Date:  1987-03       Impact factor: 6.167

8.  GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein.

Authors:  P P Humphrey; W Feniuk; M J Perren; H E Connor; A W Oxford; L H Coates; D Butina
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

9.  Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes.

Authors:  C Waeber; P Schoeffter; J M Palacios; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

10.  Canine basilar artery contractions mediated by 5-hydroxytryptamine1A receptors.

Authors:  S J Peroutka; S Huang; G S Allen
Journal:  J Pharmacol Exp Ther       Date:  1986-06       Impact factor: 4.030

View more
  16 in total

1.  Effect of the thromboxane A2-mimetic U46619 on 5-HT1-like and 5-HT2 receptor-mediated contraction of the rabbit isolated femoral artery.

Authors:  S J MacLennan; G R Martin
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

Review 2.  Rationale for the use of 5-HT1-like agonists in the treatment of migraine.

Authors:  W Feniuk; P P Humphrey; M J Perren; H E Connor; E T Whalley
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

3.  The vasomotor effects of 5-hydroxytryptamine on equine basilar arteries in vitro.

Authors:  A Miyamoto; T Obi; A Nishio
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

4.  Serotonin receptor cDNA cloned from Lymnaea stagnalis.

Authors:  K S Sugamori; R K Sunahara; H C Guan; A G Bulloch; C P Tensen; P Seeman; H B Niznik; H H Van Tol
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

5.  5-HT1B receptors mediate potent contractile responses to 5-HT in rat caudal artery.

Authors:  D A Craig; G R Martin
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

Review 6.  Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache.

Authors:  K L Dechant; S P Clissold
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

7.  Studies on the mechanism of 5-HT1 receptor-induced smooth muscle contraction in dog saphenous vein.

Authors:  M J Sumner; W Feniuk; J D McCormick; P P Humphrey
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

8.  5-HT1-like receptor mediated changes in porcine carotid haemodynamics: are 5-HT1D receptors involved?

Authors:  M O Den Boer; C M Villalón; P R Saxena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

9.  The 5-HT1-like receptor mediating the increase in canine external carotid blood flow: close resemblance to the 5-HT1D subtype.

Authors:  C M Villalón; J A Terrón
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

10.  Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathectomized dogs.

Authors:  C M Villalón; E Ramírez-San Juan; C Castillo; E Castillo; F J López-Muñoz; J A Terrón
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.